The EDGE

How to manage mantle cell lymphoma

M Dreyling, S Ferrero and O Hermine

Leukemia 2014 28: 2117-2130; advance online publication, May 23, 2014; 10.1038/leu.2014.171

Reviews

The emerging roles of DOT1L in leukemia and normal development

C M McLean, I D Karemaker and F van Leeuwen

Leukemia 2014 28: 2131-2138; advance online publication, May 23, 2014; 10.1038/leu.2014.169

Novel myelofibrosis treatment strategies: potential partners for combination therapies

B L Stein, R Swords, A Hochhaus and F Giles

Leukemia 2014 28: 2139-2147; advance online publication, June 3, 2014; 10.1038/leu.2014.176

Original Articles

Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) OPEN

S Borkowska, M Suszynska, K Mierzejewska, A Ismail, M Budkowska, D Salata, B Dolegowska, M Kucia, J Ratajczak and M Z Ratajczak

Leukemia 2014 28: 2148-2154; advance online publication, March 26, 2014; 10.1038/leu.2014.115

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

W Fiskus, S Sharma, B Shah, B P Portier, S G T Devaraj, K Liu, S P Iyer, D Bearss and K N Bhalla

Leukemia 2014 28: 2155-2164; advance online publication, April 4, 2014; 10.1038/leu.2014.119

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia

A Chorzalska, I Salloum, H Shafqat, S Khan, P Marjon, D Treaba, C Schorl, J Morgan, C R Bryke, V Falanga, T C Zhao, J Reagan, E Winer, A J Olszewski, A S Al-Homsi, N Kouttab and P M Dubielecka

Leukemia 2014 28: 2165-2177; advance online publication, April 4, 2014; 10.1038/leu.2014.120

Heparanase enhances myeloma progression via CXCL10 downregulation

U Barash, Y Zohar, G Wildbaum, K Beider, A Nagler, N Karin, N Ilan and I Vlodavsky

Leukemia 2014 28: 2178-2187; advance online publication, April 4, 2014; 10.1038/leu.2014.121

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

S E M Herman, C U Niemann, M Farooqui, J Jones, R Z Mustafa, A Lipsky, N Saba, S Martyr, S Soto, J Valdez, J A Gyamfi, I Maric, K R Calvo, L B Pedersen, C H Geisler, D Liu, G E Marti, G Aue and A Wiestner

Leukemia 2014 28: 2188-2196; advance online publication, April 4, 2014; 10.1038/leu.2014.122

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis

J Bertacchini, M Guida, B Accordi, L Mediani, A M Martelli, P Barozzi, E Petricoin, III, L Liotta, G Milani, M Giordan, M Luppi, F Forghieri, A De Pol, L Cocco, G Basso and S Marmiroli

Leukemia 2014 28: 2197-2205; advance online publication, April 4, 2014; 10.1038/leu.2014.123

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

M M Patnaik, R Itzykson, T L Lasho, O Kosmider, C M Finke, C A Hanson, R A Knudson, R P Ketterling, A Tefferi and E Solary

Leukemia 2014 28: 2206-2212; advance online publication, April 3, 2014; 10.1038/leu.2014.125

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

S J Busfield, M Biondo, M Wong, H S Ramshaw, E M Lee, S Ghosh, H Braley, C Panousis, A W Roberts, S Z He, D Thomas, L Fabri, G Vairo, R B Lock, A F Lopez and A D Nash

Leukemia 2014 28: 2213-2221; advance online publication, April 7, 2014; 10.1038/leu.2014.128

Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling

P V Spirin, T D Lebedev, N N Orlova, A S Gornostaeva, M M Prokofjeva, N A Nikitenko, S E Dmitriev, A A Buzdin, N M Borisov, A M Aliper, A V Garazha, P M Rubtsov, C Stocking and V S Prassolov

Leukemia 2014 28: 2222-2228; advance online publication, April 14, 2014; 10.1038/leu.2014.130

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma

S B Amin, W-K Yip, S Minvielle, A Broyl, Y Li, B Hanlon, D Swanson, P K Shah, P Moreau, B van der Holt, M van Duin, F Magrangeas, P Pieter Sonneveld, K C Anderson, C Li, H Avet-Loiseau and N C Munshi

Leukemia 2014 28: 2229-2234; advance online publication, April 15, 2014; 10.1038/leu.2014.140

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis

M Stern, L C de Wreede, R Brand, A van Biezen, P Dreger, M Mohty, T M de Witte, N Kröger and T Ruutu for the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Leukemia 2014 28: 2235-2240; advance online publication, April 30, 2014; 10.1038/leu.2014.145

Letters to the Editor

Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes

A Poloni, G Maurizi, D Mattiucci, S Amatori, B Fogliardi, B Costantini, M Mariani, S Mancini, A Olivieri, M Fanelli and P Leoni

Leukemia 2014 28: 2241-2244; advance online publication, June 19, 2014; 10.1038/leu.2014.197

Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas

A Nicolae, L Xi, S Pittaluga, Z Abdullaev, S D Pack, J Chen, T A Waldmann, E S Jaffe and M Raffeld

Leukemia 2014 28: 2244-2248; advance online publication, June 20, 2014; 10.1038/leu.2014.200

The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing

Y Liu, F R Abdul Razak, M Terpstra, F C Chan, A Saber, M Nijland, G van Imhoff, L Visser, R Gascoyne, C Steidl, J Kluiver, A Diepstra, K Kok and A van den Berg

Leukemia 2014 28: 2248-2251; advance online publication, June 20, 2014; 10.1038/leu.2014.201

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-x_L dependence with alvocidib response

W E Pierceall, S L Warner, R J Lena, C Doykan, N Blake, M Elashoff, D V Hoff, D J Bearss, M H Cardone, L Andritsos, J C Byrd, M C Lanasa, M R Grever and A J Johnson

Leukemia 2014 28: 2251-2254; advance online publication, July 3, 2014; 10.1038/leu.2014.206

Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma

N Weinhold, A Försti, M I da Silva Filho, J Nickel, C Campo, P Hoffmann, M M Nöthen, D Hose, H Goldschmidt, A Jauch, C Langer, U Hegenbart, S O Schönland and K Hemminki

Leukemia 2014 28: 2254-2256; advance online publication, July 3, 2014; 10.1038/leu.2014.208

Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis

P M Gordon, Stuart Dias and D A Williams

Leukemia 2014 28: 2257-2260; advance online publication, July 17, 2014; 10.1038/leu.2014.212

Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens

K Hohloch, S Zeynalova, G Held, M Ziepert, M Loeffler, G Wulf, N Schmitz, M Pfreundschuh and L Trümper on behalf of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Leukemia 2014 28: 2260-2263; advance online publication, July 9, 2014; 10.1038/leu.2014.213

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

H A F Stessman, A Lulla, T Xia, A Mitra, T Harding, A Mansoor, C L Myers, B G Van Ness and N G Dolloff

Leukemia 2014 28: 2263-2267; advance online publication, July 9, 2014; 10.1038/leu.2014.214

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

G Barosi, M-J Zhang and R Peter Gale

Leukemia 2014 28: 2267-2270; advance online publication, July 16, 2014; 10.1038/leu.2014.220

Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model

K Arita, S Tsuzuki, K Ohshima, T Sugiyama and M Seto

Leukemia 2014 28: 2270-2272; advance online publication, July 18, 2014; 10.1038/leu.2014.224